Description:

NOVEL SMALL MOLECULE DRUG ENTITIES TARGETING AMINERGIC G PROTEIN-COUPLED RECEPTORS

INV-14098

INVENTORS: Raymond G. Booth

 

Description       

Currently available pharmacotherapies for treating cognitive dysfunctions in neuropsychiatric disorders are inadequate as they are incapable of reversing the associated cognitive disruptions such as inattention, impulsivity, and memory deficit. Moreover, the existing therapies have comparatively low efficacy and are associated with various side effects such as toxicity and weight gain. This invention relates to the development and use of novel drug entities (4-phenyl-1,2,3,4-tetrahydronaphthalen-2-amine (phenylaminotetralin, PAT) analogs) targeting aminergic GPCRs associated with such disorders.

 

Value Proposition

The drug entities:

•Are non-toxic and highly efficient

•Are capable of reversing a variety of disrupted cognitive/behavioral processes

•Do not cause undesirable side effects as observed with conventional therapies

•Have a unique 5HT2A/2B receptor inverse agonist/antagonist activity together with 5HT2C receptor agonist activity in the same monovalent small molecule

•Do not have stimulant or sedative properties and are unlikely to be addictive as compared to conventional therapies

•Would be commercially useful for treatment of various neuropsychiatric, cardiovascular, and metabolic disorders

 

Intellectual Property status

Provisional Application 62/000,286

License status

Available for license

 

Patent Information:
For Information, Contact:
Mark Saulich
Associate Director of Commercialization
Northeastern University
m.saulich@northeastern.edu
Inventors:
Raymond Booth
Keywords:
Drug Discovery & Development
Drugs
Health
Medical